L de Girolamo1, M Viganò2, E Galliera3,4, D Stanco2, S Setti5, M G Marazzi6, G Thiebat7, M M Corsi Romanelli6,8, V Sansone6,9. 1. Orthopaedic Biotechnology Laboratory, IRCCS Istituto Ortopedico Galeazzi, Via R. Galeazzi, 4, 20161, Milan, Italy. laura.degirolamo@grupposandonato.it. 2. Orthopaedic Biotechnology Laboratory, IRCCS Istituto Ortopedico Galeazzi, Via R. Galeazzi, 4, 20161, Milan, Italy. 3. Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Università degli Studi di Milano, Milan, Italy. 4. IRCCS Istituto Ortopedico Galeazzi, Milan, Italy. 5. IGEA SpA, Clinical Biophysics, Carpi, Italy. 6. Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy. 7. Sport Traumatology Unit, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy. 8. IRCCS Policlinico San Donato, San Donato Milanese, Italy. 9. Orthopaedic Department, Istituto Ortopedico Galeazzi, Milan, Italy.
Abstract
PURPOSE: Chronic tendinopathy is a degenerative process causing pain and disability. Current treatments include biophysical therapies, such as pulsed electromagnetic fields (PEMF). The aim of this study was to compare, for the first time, the functional in vitro response of human tendon cells to different dosages of PEMF, varying in field intensity and duration and number of exposures. METHODS: Tendon cells, isolated from human semitendinosus and gracilis tendons (hTCs; n = 6), were exposed to different PEMF treatments (1.5 or 3 mT for 8 or 12 h, single or repeated treatments). Scleraxis (SCX), COL1A1, COL3A1 and vascular endothelial growth factor-A (VEGF-A) expression and cytokine production were assessed. RESULTS: None of the different dosages provoked apoptotic events. Proliferation of hTCs was enhanced by all treatments, whereas only 3 mT-PEMF treatment increased cell viability. However, the single 1.5 mT-PEMF treatment elicited the highest up-regulation of SCX, VEGF-A and COL1A1 expression, and it significantly reduced COL3A1 expression with respect to untreated cells. The treated hTCs showed a significantly higher release of IL-1β, IL-6, IL-10 and TGF-β. Interestingly, the repeated 1.5 mT-PEMF significantly further increased IL-10 production. CONCLUSIONS: 1.5 mT-PEMF treatment was able to give the best results in in vitro healthy human tendon cell culture. Although the clinical relevance is not direct, this investigation should be considered an attempt to clarify the effect of different PEMF protocols on tendon cells, in particular focusing on the potential applicability of this cell source for regenerative medicine purpose, both in surgical and in conservative treatment for tendon disorders.
PURPOSE:Chronic tendinopathy is a degenerative process causing pain and disability. Current treatments include biophysical therapies, such as pulsed electromagnetic fields (PEMF). The aim of this study was to compare, for the first time, the functional in vitro response of human tendon cells to different dosages of PEMF, varying in field intensity and duration and number of exposures. METHODS: Tendon cells, isolated from human semitendinosus and gracilis tendons (hTCs; n = 6), were exposed to different PEMF treatments (1.5 or 3 mT for 8 or 12 h, single or repeated treatments). Scleraxis (SCX), COL1A1, COL3A1 and vascular endothelial growth factor-A (VEGF-A) expression and cytokine production were assessed. RESULTS: None of the different dosages provoked apoptotic events. Proliferation of hTCs was enhanced by all treatments, whereas only 3 mT-PEMF treatment increased cell viability. However, the single 1.5 mT-PEMF treatment elicited the highest up-regulation of SCX, VEGF-A and COL1A1 expression, and it significantly reduced COL3A1 expression with respect to untreated cells. The treated hTCs showed a significantly higher release of IL-1β, IL-6, IL-10 and TGF-β. Interestingly, the repeated 1.5 mT-PEMF significantly further increased IL-10 production. CONCLUSIONS: 1.5 mT-PEMF treatment was able to give the best results in in vitro healthy human tendon cell culture. Although the clinical relevance is not direct, this investigation should be considered an attempt to clarify the effect of different PEMF protocols on tendon cells, in particular focusing on the potential applicability of this cell source for regenerative medicine purpose, both in surgical and in conservative treatment for tendon disorders.
Authors: Yun-Feng Rui; Pauline Po Yee Lui; Gang Li; Sai Chuen Fu; Yuk Wa Lee; Kai Ming Chan Journal: Tissue Eng Part A Date: 2010-05 Impact factor: 3.845
Authors: M De Mattei; M Fini; S Setti; A Ongaro; D Gemmati; G Stabellini; A Pellati; A Caruso Journal: Osteoarthritis Cartilage Date: 2006-08-14 Impact factor: 6.576
Authors: Abraham O Rodríguez-De la Fuente; Juan M Alcocer-González; J Antonio Heredia-Rojas; Cristina Rodríguez-Padilla; Laura E Rodríguez-Flores; Martha A Santoyo-Stephano; Esperanza Castañeda-Garza; Reyes S Taméz-Guerra Journal: Cell Biol Int Rep (2010) Date: 2012-03-26
Authors: Julianne Huegel; Daniel S Choi; Courtney A Nuss; Mary C C Minnig; Jennica J Tucker; Andrew F Kuntz; Erik I Waldorff; Nianli Zhang; James T Ryaby; Louis J Soslowsky Journal: J Shoulder Elbow Surg Date: 2017-11-22 Impact factor: 3.019
Authors: Marco Viganò; Valerio Sansone; Maria Cristina d'Agostino; Pietro Romeo; Carlotta Perucca Orfei; Laura de Girolamo Journal: J Orthop Surg Res Date: 2016-12-16 Impact factor: 2.359